APA (7th ed.) Citation

Y, C., D, H., S, S., H, Y., Y, N., H, M., . . . T, M. (2026). Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy. International journal of hematology, 123(1), 141. https://doi.org/10.1007/s12185-025-04091-0

Chicago Style (17th ed.) Citation

Y, Chikagawa, et al. "Epcoritamab as Bridging Therapy to Successful Second Allogeneic HSCT in Relapsed DLBCL After UCBT and CAR T Cell Therapy." International Journal of Hematology 123, no. 1 (2026): 141. https://doi.org/10.1007/s12185-025-04091-0.

MLA (9th ed.) Citation

Y, Chikagawa, et al. "Epcoritamab as Bridging Therapy to Successful Second Allogeneic HSCT in Relapsed DLBCL After UCBT and CAR T Cell Therapy." International Journal of Hematology, vol. 123, no. 1, 2026, p. 141, https://doi.org/10.1007/s12185-025-04091-0.